Dr Paul Kelly
Founding Partner & Director
| Healthcare
| Location: Sydney, AU
Paul is a Founding Partner of OneVentures, leading the Healthcare and Biotechnology practice. He serves as Fund Lead and Chair of the Investment Committee for Healthcare Fund III and is a voting member of the Investment Committees for Funds I, II, III and V.
With over 30 years of experience in biomedical innovation, Paul provides strategic guidance to portfolio companies. He is Chair of Vaxxas and a Non-Executive Director for BiVACOR and Prota Therapeutics. Previously, he served on the boards of Hatchtech (Chair, licensed to NYSE: DRL), CharmHealth (acquired by ASX: CGL), Clinical Genomics (Enterix acquired by 3TM), Blade and Find Me.
As co-founder of Gemini Genomics (Nasdaq: GMNI), he led one of the UK’s largest biotech IPOs (US$250M valuation) before its merger with Sequenom (Nasdaq: SQNM). Earlier in his career, he co-founded Agamatrix, a bio-sensing medical device company operating in the US and Southeast Asia as well as Atomera (Nasdaq: ATMR). As CEO of Orchid Cellmark (Nasdaq: ORCH), he drove a tenfold valuation increase and significant revenue growth.
Paul began his career as a researcher and endocrinologist at St Vincent’s Hospital Sydney before transitioning into biotechnology. In the US, he held executive roles in leading biotech and medical companies driving the growth of several industry leaders.
He has authored over 100 publications in leading journals and is a Non-Executive Director at the Garvan Institute of Medical Research, a member of the UNSW Medicine Dean’s Advisory Group and serves on the Advisory Board of the Australian Government’s Australia’s Economic Accelerator (AEA) program.
Paul holds medical degrees from UNSW and is a Fellow of the Royal Australasian College of Physicians.
| MBBS(Hons), MD, FRACP
